Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sergliflozin Etabonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 17/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 13/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sergliflozin Etabonate SCHEMBL15827906 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL621807 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL621808 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL18058588 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL8018797 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL23731198 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| SCHEMBL14634632 | 0.96 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL14634627 | 0.96 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL874080 | 0.96 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL4360297 | 0.92 | SLC5A2 (0.86) | SLC5A2SLC5A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250221-A1 | INHIBITORS OF FAPP2 AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2016-09-01 | — | — | US | disclosed |
| WO-2015011284-A2 | INHIBITORS OF FAPP2 AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2015-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250221-A1 | INHIBITORS OF FAPP2 AND USES THEREOF | GBA2, GBA1, ACER2 | SLC5A2 2100/4885SLC5A1 3068/4885CYP3A4 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.